Influenza virus vaccine (Sanofi Pasteur)

流感病毒裂解疫苗（赛诺菲巴斯德）

Report date: 2026/05/25 20:02:40

Base Information

Drug NameInfluenza virus vaccine (Sanofi Pasteur)
Drug Alias Name流感病毒疫苗Trivalent influenza virus vaccine seasonalFluzone PediatricVaxigripFluzone +[6] 
ClassificationVaccines > Biological material > Viral vaccineVaccines > Application > Prophylactic vaccineVaccines > National Immunization Program > Non-immunization program vaccine(Class II)
Mechanisms of ActionImmunostimulants
TargetsNot applicable
Therapy Area/IndicationsRejection of organ transplantationHaemophilus Parainfluenzae InfectionsMetapneumovirus infections +[17] 
Global Approved IndicationsInfluenza, Human
Approved Indications in ChinaInfluenza, Human
Original Approved Country/TerritoryN/A
Original Approved Date1968/01/01
Country/TerritoryBelgiumUnited StatesPuerto Rico +[15] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesSanofi
China Registration ClassN/A

Develop Information

Active CompaniesUniversity Of BrawijayaDana-Farber Cancer InstituteSanofi +[6] 
Inactive CompaniesTribhuvan UniversityYale UniversityJohns Hopkins Bloomberg School Of Public Health +[7] 
Active IndicationsRejection of organ transplantationHaemophilus Parainfluenzae InfectionsMetapneumovirus infections +[11] 
Inactive IndicationsCollagen DiseasesDermatitis, AtopicNeoplasms +[6] 

Other Information

ATC CodeJ07BB02
Related LinksN/A